Liquidia Corp (LQDA): Shareholders' Equity
$44.75M
As of 2025-12-31
$195.11M
As of 2026-06-30
-20.9%
3-year compound annual growth
-8.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $44.75M | -43.6% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $79.38M | +67.8% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $47.29M | -47.7% | 2026-03-05, Balance as of period end |
| 2022-12-31 | $90.42M | +38.5% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $65.27M | -8.2% | 2023-03-20, Balance as of period end |
| 2020-12-31 | $71.09M | +103.4% | 2022-03-17, Balance as of period end |
| 2019-12-31 | $34.95M | n/a | 2021-03-25, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Liquidia Corp (LQDA) | 2025-12-31 | $44.75M | -43.6% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $14.33M | n/m |
| Macrogenics Inc (MGNX) | 2025-12-31 | $55.59M | -52.1% |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $98.88M | +84.8% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$292.93M | n/m |
| Syndax Pharmaceuticals Inc (SNDX) | 2025-12-31 | $64.63M | -77.6% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$438.17M | n/m |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $502.64M | +25.1% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $33.59M | -3.0% |
Compare LQDA, HRTX, MGNX, ELTP side by side · Screen every company in Pharmaceutical Preparations ↗